NewsRoom Articles - BioMedWire (BMW)

FridayNov 14, 2025 10:00 am

Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer

A study that was recently published by a team of UC San Diego researchers has found that colon cancer patients who were also taking GLP-1 medications, such as Ozempic and Wegovy, had a 50% lower mortality rate when compared to colon cancer patients that didn’t use these medications. While these findings don’t suggest a causative effect, the researchers posit that the metabolic and anti-inflammatory effects of the GLP-1 drugs could be playing a role in reducing mortality among cancer patients. For their study, the team analyzed the medical records of at least 6,800 patients that had been diagnosed with colon…

FridayNov 14, 2025 9:45 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John Climaco emphasized the company’s commitment to overcoming the blood-brain barrier, a key obstacle in brain cancer therapy. Lead candidate TPI 287, an abeotaxane, has shown early evidence of appearing to cross the blood-brain barrier and producing clinical responses. Phase 2 planning is underway following encouraging data from a Phase 1 combination study with bevacizumab (Avastin). The company’s repurposed global clinical network and regulatory progress position it for potential late-stage development in 2026. TPI 287 holds multiple Orphan Drug Designations, covering gliomas, neuroblastoma, and other CNS-related…

ThursdayNov 13, 2025 11:15 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership

Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually. The HeartBeam System enables a patient to capture a 30-second ECG recording with its credit-card-sized, cable-free device, regardless of where they are. The HeartBeam-HeartNexus collaboration makes board-certified cardiologists available 24/7 to interpret the results for arrhythmia assessment and provide expert feedback directly to the patient or to a coordinating clinician. HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus (https://ibn.fm/yyz1i). The partnership will expand access to cardiologist-level ECG insights for…

ThursdayNov 13, 2025 10:00 am

Rarest Natural Element Promises to Revolutionize How Cancer is Treated

Scientists at Texas A&M University have unlocked a new way that involves leveraging the rarest natural element, astatine-211, to kill cancer cells. This form of radiotherapy eliminates malignant cells while leaving the healthy tissues surrounding the cancer unaffected. One of the biggest challenges that have plagued conventional cancer therapies like chemotherapy and radiotherapy is that the treatments are indiscriminate and impact both cancerous tissues and healthy cells. As a result, these treatments cause side effects that can often be very serious or even life-threatening. The use of astatine-211 promises to address this drawback of existing radiotherapy approaches. Astatine (a Greek…

TuesdayNov 11, 2025 10:00 am

US Senators Reach Deal to Reopen Government

A group of Senate Democrats has agreed to re-open the government, at least until January, without receiving a guarantee that their key demand of extending healthcare insurance subsidies will be met by GOP lawmakers. That breakthrough was secured after the Senate held a rare session on Sunday to chart a way out of the longest ever government shutdown in the history of the country. During that session, a number of centrist Democrats negotiated with GOP Senators and the Democrats promised to vote in favor of re-opening the government on condition that they were given a promise that the chamber would…

TuesdayNov 11, 2025 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology

The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system. HeartBeam’s intellectual-property foundation is a major reason for its placement. HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in…

FridayNov 07, 2025 10:00 am

Surface Sugars on Immune Cells Linked to the Progression of Psoriasis

A new study has found that immune cells shed the sugars on their surface prior to entering the inflamed skin in people suffering from psoriasis. These findings could lay the foundation for understanding how this disease progresses and lays the groundwork for new approaches to treating psoriasis. The study, whose findings were published in the Science Signaling journal, was conducted by a team in the UK, namely, Doctor Amy Saunders who works at Lancaster University, Doctor Douglas Dyer who works at the University of Manchester, and Doctor Megan Priestley, who was a PhD student to both Sanders and Dyer. Priestley…

ThursdayNov 06, 2025 10:00 am

Review Shows That Neurocognitive Functioning Declines in Patients with CNS Cancers

A review published recently has underscored how patients afflicted with central nervous system (CNS) cancers show significant declines in neurocognitive function. This decline is driven by the location of the malignant tumors and the effects of the treatments given. The narrative review points out declines in processing speed, attention, executive function and memory. The severity and profile of this decline often varies depending on the anatomic location and the biology of the tumor. When the temporal and frontal lobes are involved, the neurocognitive function declines manifest as impacts on higher order skills which facilitate daily independence of patients and their…

ThursdayNov 06, 2025 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System

ECG data is necessary for the diagnosis of all cardiac arrhythmias in order to assess severity, implications and treatment options. HeartBeam is reporting that its 12-lead ECG synthesis software for arrhythmia assessment has been submitted to the U.S. Food and Drug Administration for 510(k) clearance. To enable smooth commercialization, the company is building the infrastructure needed to support widespread adoption. In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults (https://ibn.fm/8TSNY). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with…

TuesdayNov 04, 2025 10:00 am

Lung Cancer Screening is Still Woefully Low in the US, Report Shows

A recent report published by the American Lung Association shows that only a tiny fraction of Americans that are eligible for lung cancer screening undergo the needed screening. This is despite the fact that lung cancer accounts for 20% of all deaths in America attributed to cancer. Deaths due to lung cancer exceed the combined fatalities due to prostate, breast and colon cancer. These statistics would warrant greater rates of lung cancer screening, but on average, just a paltry 5.8% of individuals in America that should get screened actually undergo screening for this cancer, according to the ALA report. In…